A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant chemotherapy followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in patients with resectable locally advanced gastric cancer: An interim efficacy report.

被引：0
|
作者：
Kim, Hyung-Don
Ryu, Min-Hee
Park, Young Soo
Lee, Jong Seok
Kang, Yoon-Koo
机构：
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[2] Asan Med Ctr, Dept Pathol, Seoul, South Korea
[3] Asan Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
408
引用
收藏
页码：408 / 408
页数：1
相关论文
共 50 条
  • [1] Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
    Kang, Yoon-Koo
    Kim, Hyung-Don
    Cho, Hyungwoo
    Park, Young Soo
    Lee, Jong Seok
    Ryu, Min-Hee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
  • [2] A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
    Park, Inkeun
    Ryu, Min-Hee
    Choi, Yoon Hee
    Kang, Hyo Jeong
    Yook, Jeong Hwan
    Park, Young Soo
    Kim, Hyun Jin
    Jung, Hwoon-Yong
    Lee, Gin Hyug
    Kim, Kab Choong
    Kim, Byung Sik
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 815 - 823
  • [3] A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
    Inkeun Park
    Min-Hee Ryu
    Yoon Hee Choi
    Hyo Jeong Kang
    Jeong Hwan Yook
    Young Soo Park
    Hyun Jin Kim
    Hwoon-Yong Jung
    Gin Hyug Lee
    Kab Choong Kim
    Byung Sik Kim
    Yoon-Koo Kang
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 815 - 823
  • [4] PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer
    Kang, Yoon-Koo
    Yook, Jeong Hwan
    Park, Young-Kyu
    Lee, Jong Seok
    Kim, Young-Woo
    Kim, Jin Young
    Ryu, Min-Hee
    Rha, Sun Young
    Chung, Ik Joo
    Kim, In-Ho
    Oh, Sang Cheul
    Park, Young Soo
    Son, Taeil
    Jung, Mi Ran
    Heo, Mi Hwa
    Kim, Hark Kyun
    Park, ChoHyun
    Yoo, Chang Hak
    Choi, Jin-Hyuk
    Zang, Dae Young
    Jang, You Jin
    Sul, Ji Young
    Kim, Jong Gwang
    Kim, Beom Su
    Beom, Seung-Hoon
    Cho, Sang Hee
    Ryu, Seung Wan
    Kook, Myeong-Cherl
    Ryoo, Baek-Yeol
    Kim, Hyun Ki
    Yoo, Moon-Won
    Lee, Nam Su
    Lee, Sang Ho
    Kim, Gyunji
    Lee, YeonJu
    Lee, Jee Hyun
    Noh, Sung Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2903 - +
  • [5] A randomized phase III study of neoadjuvant chemotherapy with docetaxel(D), oxaliplatin(O), and S-1(S) (DOS) followed by surgery and adjuvant S-1 vs. surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY).
    Kang, Yoon-Koo
    Yook, Jeong Hwan
    Ryu, Min-Hee
    Lee, Jong Seok
    Park, Youngkyu
    Chung, Ik-Joo
    Jung, Minkyu
    Kim, Young Woo
    Kim, Mi-Jung
    Oh, Sang Cheul
    Kim, Samyong
    Kim, Jong Gwang
    Song, Hong-Suk
    Ryu, Seung Wan
    Roh, Sang Young
    Kook, Myeong-Cherl
    Shim, Kyoo Jung
    Lee, Jeehyun
    Kim, Gyunji
    Noh, Sung Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)
    Kang, Y-K.
    Yook, J. H.
    Park, Y-K.
    Kim, Y-W.
    Kim, J.
    Ryu, M-H.
    Rha, S. Y.
    Chung, I-J.
    Kim, I-H.
    Oh, S. C.
    Yoo, C-H.
    Choi, J-H.
    Zang, D. Y.
    Kim, G.
    Lee, Y.
    Noh, S-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Adjuvant Chemotherapy With S-1 Plus Docetaxel Versus S-1 Plus Oxaliplatin in Stage III Gastric Cancer
    Yamamoto, Masaaki
    Omori, Takeshi
    Shinno, Naoki
    Hara, Hisashi
    Mukai, Yosuke
    Sugase, Takahito
    Takeoka, Tomohira
    Mikamori, Manabu
    Kanemura, Takashi
    Hasegawa, Shinichiro
    Akita, Hirofumi
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Wada, Hiroshi
    Matsuda, Chu
    Yasui, Masayoshi
    Miyata, Hiroshi
    Ohue, Masayuki
    ANTICANCER RESEARCH, 2023, 43 (11) : 5015 - 5024
  • [8] Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer
    Migita, Kazuhiro
    Nashimoto, Atsushi
    Yabusaki, Hiroshi
    Matsuki, Atsushi
    Aizawa, Masaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (01) : 102 - 109
  • [9] Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer
    Kazuhiro Migita
    Atsushi Nashimoto
    Hiroshi Yabusaki
    Atsushi Matsuki
    Masaki Aizawa
    International Journal of Clinical Oncology, 2016, 21 : 102 - 109
  • [10] Safety and efficacy of neoadjuvant chemotherapy with S-1 and oxaliplatin plus apatinib for locally advanced gastric cancer.
    Zheng, Ya'nan
    Yang, Xiao
    Ni, Zhentian
    Zhu, Zhenglun
    Xu, Wei
    Yang, Zhongyin
    Liu, Wentao
    Yan, Min
    Zhu, Zhenggang
    Li, Chen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345